More so than rheumatoid arthritis (RA), psoriasis (PsO) and psoriatic arthritis (PsA) are associated with liver disease, particularly non-alcoholic fatty liver disease (NAFLD) and cirrhosis, and this was true even among patients without systemic therapy (ST) exposure, according to a recent study. Researchers performed a cohort study among patients with PsO, PsA, or RA and matched controls in The Health Improvement Network from 1994-2014. Outcomes of interest were any liver disease, NAFLD, and cirrhosis (any etiology). They found:
- Among patients with psoriasis (n=197,130), PsA (n=12,308), RA (n=54,251), and matched controls (n=1,279,754), the adjusted hazard ratios for any liver disease were elevated among patients with PsO, PsA, and RA without a ST but not elevated in RA patients prescribed a ST.
- Incident NAFLD was highest in patients with PsO prescribed a ST and PsA with a ST.
- Risk of cirrhosis was highest among patients with PsO with a ST and PsA without a ST.
- Additionally, the prevalence of liver disease and cirrhosis increased in a stepwise fashion with increasing body surface area affected by PsO.
Ogdie A, Grewal SK, Noe MH, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: A population-based study. [Published online ahead of print November 2, 2017]. J Invest Dermatol. doi:10.1016/j.jid.2017.10.024.